David Wofsy, MD

Professor Emeritus

Dr. Wofsy received his undergraduate degree from Harvard (1968), his MD from the University of California, San Diego (1974), and his medical residency training and rheumatology fellowship training from the University of California, San Francisco. He joined the UCSF faculty in 1980. He currently Professor of Medicine and Microbiology/Immunology at UCSF. Dr. Wofsy also serves as Associate Dean for Admissions for the UCSF School of Medicine. He has served on numerous NIH study sections, and on the Arthritis Advisory Committee of the Food and Drug Administration. Dr. Wofsy is a past-President of the American College of Rheumatology.

Dr. Wofsy's research program is devoted to the development of novel therapies for autoimmune diseases, particularly systemic lupus erythematosus (SLE). For many years, his research focused on the cellular and molecular mechanisms that lead to autoimmunity in murine models for SLE. These therapies are designed to block pathologic immune responses without damaging the entire immune system. One of the therapies that was pioneered by Dr. Wofsy's group involves the B7 family of molecules on antigen-presenting cells (APC). These molecules play a pivotal role in the generation of T-cell help. Specifically, the interaction of B7 molecules on APC with their ligand (designated CD28) on T cells provides an important signal for T-cell activation. Dr. Wofsy first showed that selective inhibition of the B7-CD28 interaction retards autoimmunity in murine lupus. He subsequently showed that this beneficial effect could be enhanced substantially in two ways: (i) by combining blockade of B7-CD28 with blockade of other receptor-ligand pairs (CD40-CD40L) on the surface of T cells and APC; and (ii) by combining blockade of B7-CD28 with cyclophosphamide therapy. In each case, combination therapy provided a prolonged benefit without sustained generalized immune suppression. This work laid the foundation for translational studies that resulted in FDA approval of a new treatment for rheumatoid arthritis. Dr.Wofsy's current research is focused on establishing whether this therapy can be life-saving in people with kidney disease due to SLE.

Education
2017 - Diversity, Equity, and Inclusion Champion Training, University of California
Residency, - School of Medicine, University of California, San Francisco
Honors and Awards
  • Master of the American College of Rheumatology, American College of Rheumatology, 2012
  • Paul Klemperer Award and Medal, New York Academy of Medicine, 2011
  • Lee C. Howley Sr. Prize, Arthritis Foundation, 2007
  • Arthritis Hero Award, Arthritis Foundation, 2001
  • Edmund L. Dubois Award for Outstanding Research in SLE, American College of Rheumatology, 1999
Websites
Publications

  1. Carlucci PM, Preisinger K, Deonaraine KK, Zaminski D, Dall'Era M, Gold HT, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Furie R, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao D, Weisman MH, Accelerating Medicines Partnership in RA/SLE Network, Izmirly PM, Buyon J, Petri M. Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network. Rheumatology (Oxford, England) 2024. PMID: 38530774


  2. Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Accelerating Medicines Partnership: RA/SLE Network, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. bioRxiv : the preprint server for biology 2024. PMID: 38293222


  3. Izmirly PM, Kim MY, Carlucci PM, Preisinger K, Cohen BZ, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao DA, Weisman MH, Accelerating Medicines Partnership in RA/SLE Network, Petri M, Buyon J, Furie R. Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network. Arthritis research & therapy 2024. PMID: 38378664


  4. Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, Rao DA, Arazi A, Celia AI, Putterman C, Anolik JH, Barnas J, Dall'Era M, Wofsy D, Furie R, Kamen D, Kalunian K, James JA, Guthridge J, Atta MG, Monroy Trujillo J, Fine D, Clancy R, Belmont HM, Izmirly P, Apruzzese W, Goldman D, Berthier CC, Hoover P, Hacohen N, Raychaudhuri S, Davidson A, Diamond B, Accelerating Medicines Partnership in RA/SLE network, Petri M. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI insight 2024. PMID: 38258904


  5. Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, Apruzzese W, Belmont HM, Izmirly PM, Zaminski D, Wu M, Connery S, Payan-Schober F, Furie R, Dall'Era M, Cho K, Kamen D, Kalunian K, Anolik J, Barnas J, Ishimori M, Weisman MH, Accelerating Medicines Partnership (AMP) RA/SLE Network, Buyon JP, Petri M. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. 2022. PMID: 35212719


  6. Fava A, Rao DA, Mohan C, Zhang T, Rosenberg A, Fenaroli P, Belmont HM, Izmirly P, Clancy R, Monroy Trujillo J, Fine D, Arazi A, Berthier CC, Davidson A, James JA, Diamond B, Hacohen N, Wofsy D, Raychaudhuri S, Apruzzese W, Accelerating Medicines Partnership in RA/SLE network, Buyon J, Petri M. Urine Proteomics and Renal Single Cell Transcriptomics Implicate IL-16 in Lupus Nephritis. 2021. PMID: 34783463


  7. Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery S, Payan-Schober F, Furie RA, Berthier CC, Dall'Era M, Cho K, Kamen DL, Kalunian K, Anolik J, Ishimori M, Weisman MH, Accelerating Medicines Partnership RA/SLE network , Petri MA, Buyon JP. Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. 2021. PMID: 34389634


  8. Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Schmajuk G, Tani C, Tedeschi SK, Touma Z, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Costenbader K, Johnson SR. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the rheumatic diseases 2021. PMID: 33568386


  9. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Lim SS, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis & rheumatology (Hoboken, N.J.) 2020. PMID: 32755035


  10. Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the rheumatic diseases 2020. PMID: 32816709


  11. Wofsy D. A Tale of Two Trials. Arthritis & rheumatology (Hoboken, N.J.) 2020. PMID: 32182394


  12. Fava A, Buyon JP, Mohan C, Zhang T, Belmont HM, Izmirly P, Clancy R, Monroy Trujillo J, Fine DM, Zhang Y, Magder L, Rao DA, Arazi A, Berthier CC, Davidson A, Diamond B, Hacohen N, Wofsy D, Apruzzese W, Accelerating Medicines Partnership T, Raychaudhuri S, Petri M. Integrated urine proteomics and renal single-cell genomics identify an interferon-? response gradient in lupus nephritis. JCI insight 2020. PMID: 32396533


  13. Busche K, Elks ML, Hanson JT, Jackson-Williams L, Manuel RS, Parsons WL, Wofsy D, Yuan K. The Validity of Scores from the New MCAT Exam in Predicting Student Performance: Results from a Multisite Study. Academic medicine : journal of the Association of American Medical Colleges 2019. PMID: 31425189


  14. Hoover P, Der E, Berthier CC, Arazi A, Lederer JA, James JA, Buyon J, Petri M, Belmont HM, Izmirly P, Wofsy D, Hacohen N, Diamond B, Putterman C, Davidson A. The Accelerating Medicines Partnership - Organizational Structure and Preliminary Data from the Phase 1 Studies of Lupus Nephritis. Arthritis care & research 2019. PMID: 31502417


  15. Henderson MC, Jerant A, Unkart J, Griffin EJ, Sciolla SF, Kelly CJ, Peterson EM, Hall T, Wofsy D, Fancher TL. The Relationships among Self-Designated Disadvantage, Socioeconomic Disadvantage, and Academic Performance in Medical School: A Multi-Institutional Study. 2020. PMID: 35061622


  16. Craft JE, Crow MK, Diamond B, Elkon KB, Flood J, Fox DA, Gabriel SE, Gilkeson GS, Hahn BH, Hardin JA, Koopman WJ, Lockshin MD, Salmon JE, Seaman WE, Sergent JS, Uknis AB, Weinblatt ME, Wofsy D. Georgia Abortion Law and our Commitment to Patients. Arthritis & rheumatology (Hoboken, N.J.) 2019. PMID: 31637878


  17. Rao DA, Arazi A, Wofsy D, Diamond B. Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis. Nature reviews. Nephrology 2019. PMID: 31853010


  18. Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, Muise E, Zhang KX, Arazi A, Keras G, Li ZJ, Qu Y, Gurish MF, Petri M, Buyon JP, Putterman C, Wofsy D, James JA, Guthridge JM, Diamond B, Anolik JH, Mackey MF, Alves SE, Nigrovic PA, Costenbader KH, Brenner MB, Lederer JA, Rao DA. PD-1hi CXCR5- T peripheral helper cells promote B cells responses in lupus via MAF and IL-21. JCI insight 2019. PMID: 31536480


  19. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis. Nature immunology 2019. PMID: 31409923


  20. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2019. PMID: 31385462


  21. Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P. Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatology advances in practice 2019. PMID: 31528843


  22. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the rheumatic diseases 2019. PMID: 31383717


  23. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. The immune cell landscape in kidneys of patients with lupus nephritis. Nature immunology 2019. PMID: 31209404


  24. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Tancredi DJ, Sousa FJ, Franks P. Do Admissions Multiple Mini-Interview and Traditional Interview Scores Predict Subsequent Academic Performance? A Study of Five California Medical Schools. Academic medicine : journal of the Association of American Medical Colleges 2018. PMID: 30188370


  25. Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the rheumatic diseases 2019. PMID: 30692164


  26. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD. Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2018. PMID: 30277008


  27. Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M. Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. The Journal of rheumatology 2018. PMID: 30554156


  28. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools? Academic medicine : journal of the Association of American Medical Colleges 2018. PMID: 29561273


  29. Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P. Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study. Academic medicine : journal of the Association of American Medical Colleges 2017. PMID: 29095170


  30. Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L. Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. Kidney international reports 2018. PMID: 30197972


  31. Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Annals of the rheumatic diseases 2018. PMID: 29563108


  32. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Volume 70 of Issue 4. Arthritis care & research 2018. PMID: 28692774


  33. Jerant A, Henderson MC, Griffin E, Rainwater JA, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. Reliability of Multiple Mini-Interviews and traditional interviews within and between institutions: a study of five California medical schools. Volume 17 of Issue 1. BMC medical education 2017. PMID: 29110662


  34. Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D. Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Volume 4 of Issue 1. Lupus science & medicine 2017. PMID: 29214037


  35. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Volume 69 of Issue 1. Arthritis & rheumatology (Hoboken, N.J.) 2016. PMID: 27390168


  36. Wofsy D. In memoriam: Ephraim P. Engleman, MD, 1911-2015. Volume 67 of Issue 11. Arthritis & rheumatology (Hoboken, N.J.) 2015. PMID: 26508466


  37. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Volume 2 of Issue 1. Lupus science & medicine 2015. PMID: 26023331


  38. Wofsy D, Diamond B, Houssiau FA. Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Volume 67 of Issue 5. Arthritis & rheumatology (Hoboken, N.J.) 2015. PMID: 25779381


  39. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Volume 74 of Issue 11. Annals of the rheumatic diseases 2014. PMID: 24951103


  40. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Volume 65 of Issue 6. Arthritis and rheumatism 2013. PMID: 23529285


  41. Wofsy D. Recent progress in conventional and biologic therapy for systemic lupus erythematosus. Volume 72 Suppl 2. Annals of the rheumatic diseases 2012. PMID: 23253930


  42. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Volume 64 of Issue 11. Arthritis and rheumatism 2012. PMID: 22806274


  43. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. Volume 365 of Issue 20. The New England journal of medicine 2011. PMID: 22087680


  44. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. Volume 38 of Issue 5. The Journal of rheumatology 2011. PMID: 21285160


  45. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Volume 63 of Issue 3. Arthritis care & research 2010. PMID: 21080348


  46. Papadakis MA, Wofsy D. Plagiarism on personal statements: a disturbing symptom of a broader trend. Volume 153 of Issue 2. Annals of internal medicine 2010. PMID: 20643994


  47. Dall'Era M, Wofsy D. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Volume 6 of Issue 3. Nature reviews. Rheumatology 2010. PMID: 20197774


  48. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Volume 9 of Issue 44. Discovery medicine 2010. PMID: 20102681


  49. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Volume 62 of Issue 1. Arthritis and rheumatism 2010. PMID: 20039429


  50. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Volume 49 of Issue 1. Rheumatology (Oxford, England) 2009. PMID: 19933596


  51. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Volume 5 of Issue 10. Nature reviews. Rheumatology 2009. PMID: 19798031


  52. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Volume 5 of Issue 6. Nature reviews. Rheumatology 2009. PMID: 19491915


  53. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Volume 20 of Issue 5. Journal of the American Society of Nephrology : JASN 2009. PMID: 19369404


  54. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. Volume 301 of Issue 13. JAMA 2009. PMID: 19336712


  55. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E. A quality indicator set for systemic lupus erythematosus. Volume 61 of Issue 3. Arthritis and rheumatism 2009. PMID: 19248127


  56. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Volume 56 of Issue 12. Arthritis and rheumatism 2007. PMID: 18050206


  57. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Volume 16 of Issue 12. Lupus 2007. PMID: 18042591


  58. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Volume 18 of Issue 5. Current opinion in rheumatology 2006. PMID: 16896285


  59. Daikh DI, Gillis J, Wofsy D. Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases. Volume 55 of Issue 2. Arthritis and rheumatism 2006. PMID: 16583382


  60. Wofsy D. Living in a different world. Volume 52 of Issue 2. Arthritis and rheumatism 2005. PMID: 15692996


  61. Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Volume 14 of Issue 3. Lupus 2005. PMID: 15807196


  62. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Volume 46 of Issue 12. Arthritis and rheumatism 2002. PMID: 12483729


  63. Wofsy D, Daikh DI. Treatment of autoimmune diseases by inhibition of T-cell costimulation. Volume 12 of Issue 1. Modern rheumatology 2002. PMID: 24383824


  64. Diamond B, Bluestone J, Wofsy D. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis and rheumatism 2001. PMID: 11508422


  65. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. Journal of immunology (Baltimore, Md. : 1950) 2001. PMID: 11207238


  66. Wada T, Schwarting A, Chesnutt MS, Wofsy D, Rubin Kelley V. Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets. Kidney international 2001. PMID: 11168938


  67. Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. The Journal of rheumatology 2001. PMID: 11196549


  68. Daikh DI, Wofsy D. Treatment of autoimmunity by inhibition of T cell costimulation. Advances in experimental medicine and biology 2001. PMID: 11505969


  69. Jeddi P, Keusch J, Lydyard PM, Bodman-Smith KB, Chesnutt MS, Wofsy D, Hirota H, Taga T, Delves PJ. The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G. Immunology 1999. PMID: 10583610


  70. Daikh DI, Wofsy D. Effects of anti-B7 monoclonal antibodies on humoral immune responses. Volume 12 of Issue 2. Journal of autoimmunity 1999. PMID: 10047430


  71. Daikh DI, Wofsy D. On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Volume 30 of Issue 8. Transplantation proceedings 1998. PMID: 9865285


  72. Wofsy D, Daikh DI. Opportunities for future biological therapy in SLE. Volume 12 of Issue 3. Bailliere's clinical rheumatology 1998. PMID: 9890111


  73. Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice. Volume 87 of Issue 1. Clinical immunology and immunopathology 1998. PMID: 9576007


  74. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. Volume 159 of Issue 7. Journal of immunology (Baltimore, Md. : 1950) 1997. PMID: 9317105


  75. Daikh D, Wofsy D, Imboden JB. The CD28-B7 costimulatory pathway and its role in autoimmune disease. Volume 62 of Issue 2. Journal of leukocyte biology 1997. PMID: 9261329


  76. Adleman LM, Wofsy D. Blind T-cell homeostasis in CD4-deficient mice. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996. PMID: 8601219


  77. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Volume 265 of Issue 5176. Science (New York, N.Y.) 1994. PMID: 7520604


  78. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. Volume 94 of Issue 2. The Journal of clinical investigation 1994. PMID: 8040314


  79. Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D. Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Volume 72 of Issue 2. Clinical immunology and immunopathology 1994. PMID: 8050193


  80. Wofsy D. Recent advances in the treatment of rheumatic diseases: new approaches to immunotherapy. Ryumachi. [Rheumatism] 1994. PMID: 8202830


  81. Adleman LM, Wofsy D. T-cell homeostasis: implications in HIV infection . Journal of acquired immune deficiency syndromes 1993. PMID: 8094457


  82. Wofsy D. Treatment of murine lupus with anti-CD4 monoclonal antibodies. Immunology series 1993. PMID: 8096400


  83. Finck BK, Yung CM, Carteron NL, Wofsy D. The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies. Clinical immunology and immunopathology 1992. PMID: 1360341


  84. Connolly K, Roubinian JR, Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. Volume 149 of Issue 9. Journal of immunology (Baltimore, Md. : 1950) 1992. PMID: 1357036


  85. Jäck HM, Beck-Engeser G, Lee G, Wofsy D, Wabl M. Tumorigenesis mediated by an antigen receptor. Proceedings of the National Academy of Sciences of the United States of America 1992. PMID: 1528851


  86. Wofsy D, Carteron NL. CD4 antibody therapy in systemic lupus erythematosus. Volume 2 of Issue 6. Seminars in immunology 1990. PMID: 2104279


  87. Carteron NL, Wofsy D, Schimenti C, Ermak TH. F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T cells, CD8+ T cells, and B cells in the kidneys of lupus-prone NZB/NZW mice. Volume 56 of Issue 3. Clinical immunology and immunopathology 1990. PMID: 1975226


  88. Wofsy D. Regulation of immunity by anti-T-cell antibodies. The Western journal of medicine 1990. PMID: 2219889


  89. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. Volume 144 of Issue 5. Journal of immunology (Baltimore, Md. : 1950) 1990. PMID: 2307839


  90. Ermak TH, Steger HJ, Wofsy D. Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node. Laboratory investigation; a journal of technical methods and pathology 1989. PMID: 2529396


  91. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Volume 52 of Issue 3. Clinical immunology and immunopathology 1989. PMID: 2758698


  92. Erlich KS, Wofsy D, Dix RD, Mills J. Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis. Volume 52 of Issue 2. Clinical immunology and immunopathology 1989. PMID: 2525439


  93. Carteron NL, Schimenti CL, Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. Volume 142 of Issue 5. Journal of immunology (Baltimore, Md. : 1950) 1989. PMID: 2521880


  94. Klippel JH, Strober S, Wofsy D. New therapies for the rheumatic diseases. Bulletin on the rheumatic diseases 1989. PMID: 2670022


  95. Wofsy D, Chiang NY, Greenspan JS, Ermak TH. Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune disease. Volume 1 of Issue 5. Journal of autoimmunity 1988. PMID: 3267085


  96. Wofsy D. The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus. Volume 1 of Issue 2. Journal of autoimmunity 1988. PMID: 2978113


  97. Carteron NL, Wofsy D, Seaman WE. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. Volume 140 of Issue 3. Journal of immunology (Baltimore, Md. : 1950) 1988. PMID: 2448372


  98. Seaman WE, Wofsy D. Selective manipulation of the immune response in vivo by monoclonal antibodies. Annual review of medicine 1988. PMID: 3285774


  99. Wofsy D. Treatment of autoimmune diseases with monoclonal antibodies. Progress in allergy 1988. PMID: 3064092


  100. Wofsy D. New approaches to treating systemic lupus erythematosus. The Western journal of medicine 1987. PMID: 3310402


  101. Wofsy D, Chiang NY. Proliferation of Ly-1 B cells in autoimmune NZB and (NZB x NZW)F1 mice. European journal of immunology 1987. PMID: 2954827


  102. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. Journal of immunology (Baltimore, Md. : 1950) 1987. PMID: 3106478


  103. Gutstein NL, Wofsy D. Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. Journal of immunology (Baltimore, Md. : 1950) 1986. PMID: 3097122


  104. Woodcock J, Wofsy D, Eriksson E, Scott JH, Seaman WE. Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells. Transplantation 1986. PMID: 2947360


  105. Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. Journal of immunology (Baltimore, Md. : 1950) 1986. PMID: 3090139


  106. Wofsy D. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. Volume 136 of Issue 12. Journal of immunology (Baltimore, Md. : 1950) 1986. PMID: 3086436


  107. Stanton T, Stevens TL, Ledbetter JA, Wofsy D. Anti-Ly-1 antibody induces interleukin 2 release from T cells. Journal of immunology (Baltimore, Md. : 1950) 1986. PMID: 3081630


  108. Wofsy D, Seaman WE. Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4. Immunologic research 1986. PMID: 3093610


  109. Wofsy D. Strategies for treating autoimmune disease with monoclonal antibodies. The Western journal of medicine 1985. PMID: 3911593


  110. Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. Journal of immunology (Baltimore, Md. : 1950) 1985. PMID: 3928743


  111. Wofsy D, Mayes DC, Woodcock J, Seaman WE. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. Journal of immunology (Baltimore, Md. : 1950) 1985. PMID: 3160776


  112. Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. The Journal of experimental medicine 1985. PMID: 3919141


  113. Wofsy D, Ledbetter JA, Hendler PL, Seaman WE. Treatment of murine lupus with monoclonal anti-T cell antibody. Volume 134 of Issue 2. Journal of immunology (Baltimore, Md. : 1950) 1985. PMID: 3871218


  114. Wofsy D. [Not Available]. Volume 5 of Issue 7. Immunology today 1984. PMID: 25289950


  115. Wofsy D. Hormones, handedness, and autoimmunity. Volume 5 of Issue 6. Immunology today 1984. PMID: 25289744


  116. Wofsy D, Hardy RR, Seaman WE. The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T cells that is involved in the response to class II major histocompatibility antigens. Journal of immunology (Baltimore, Md. : 1950) 1984. PMID: 6144707


  117. Wofsy D, Kerger CE, Seaman WE. Monocytosis in the BXSB model for systemic lupus erythematosus. The Journal of experimental medicine 1984. PMID: 6363600


  118. Seaman WE, Wofsy D, Greenspan JS, Ledbetter JA. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. Journal of immunology (Baltimore, Md. : 1950) 1983. PMID: 6187819


  119. Shear HL, Wofsy D, Talal N. Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. Clinical immunology and immunopathology 1983. PMID: 6872348


  120. Talal N, Dauphinee MJ, Wofsy D. Interleukin-2 deficiency, genes, and systemic lupus erythematosus. Volume 25 of Issue 7. Arthritis and rheumatism 1982. PMID: 6285934


  121. Wofsy D, Ledbetter JA, Roubinian JR, Seaman WE, Talal N. Thymic influences on autoimmunity in MRL-lpr mice. Scandinavian journal of immunology 1982. PMID: 6981841


  122. Dauphinée MJ, Kipper SB, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. Journal of immunology (Baltimore, Md. : 1950) 1981. PMID: 6975325


  123. Wofsy D, Murphy ED, Roths JB, Dauphinée MJ, Kipper SB, Talal N. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. The Journal of experimental medicine 1981. PMID: 6975351


  124. Wofsy D, Dauphinée MJ, Kipper SB, Talal N. Interleukin-2 deficiency in murine systemic lupus erythematosus. Transactions of the Association of American Physicians 1981. PMID: 6979821


  125. Wofsy D. Culture-negative septic arthritis and bacterial endocarditis. Diagnosis by synovial biopsy. Arthritis and rheumatism 1980. PMID: 6990934


  126. Loeb JM, Livermore BM, Wofsy D. Coccidioidomycosis of the thyroid. Annals of internal medicine 1979. PMID: 475170